Copyright
©The Author(s) 2016.
World J Gastrointest Oncol. Jul 15, 2016; 8(7): 555-562
Published online Jul 15, 2016. doi: 10.4251/wjgo.v8.i7.555
Published online Jul 15, 2016. doi: 10.4251/wjgo.v8.i7.555
Table 4 Mean times to disease progression and death according to the neutrophil-to-lymphocyte ratio and the C-reactive protein/albumin ratio
| Variable | NLR ≤ 5 | NLR > 5 | P value | CRP/albumin ratio ≤ 0.5 | CRP/albumin ratio > 0.5 | P value |
| Time until disease progression, mean ± SD), mo | 3.0 ± 1.7 | 1.9 ± 1.2 | 0.016 | 3.0 ± 1.8 | 2.3 ± 1.4 | 0.08 |
| Time until death, mean ± SD, mo | 9.3 ± 5.9 | 4.7 ± 3.5 | 0.014 | 10.0 ± 5.4 | 6.0 ± 5.5 | 0.01 |
- Citation: Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562
- URL: https://www.wjgnet.com/1948-5204/full/v8/i7/555.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v8.i7.555